⌕
Madrigal Pharmaceuticals · MDGL · Nasdaq
Tenet 32 · Weak
Compare
$421.99−0.46%At closeTenet 32 · Weak
$421.99−1.97 (−0.46%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Madrigal Pharmaceuticals (MDGL) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

14 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue history is too short to read a growth trend, net margin −30.1%. Worth your attention in FY25: Share count (+35.7%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲432.1%
958.4
FY21→FY25CAGR —
Net income ($M)▲38.1%
−288.3
FY21→FY25CAGR —
Free cash flow ($M)▲58.4%
−190.0
FY21→FY25CAGR —
Diluted EPS▲41.3%
−12.85
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+35.7%

16.5mn → 22.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$467.0K

−68.1% YoY in FY25 · 0.0% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)958.4Revenue0.0COGS−388.5R&D−870.0SG&A−300.1Op income11.8Tax & other−288.3Net income

-30¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Operating Net
108530%sector median net margin ~3%FY21FY25

Net margin -30.1% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7401, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
1,427,940.0958,403.0180,133.00.00.00.0▲432.1%—
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—A—A—A0.00.00.0——
Research & development
387,893.0388,525.0236,718.0272,350.0245,441.0205,164.0▲64.1%+17.3%
Selling, general & admin
1,192,698.0869,975.0441,290.0108,146.048,130.037,318.0▲97.1%+119.7%
Total operating expenses
1,580,591.01,258,500.0678,008.0380,496.0293,571.0242,482.0▲85.6%+50.9%
Operating incomefeeds ROC rank
−152,651.0−300,097.0−497,875.0−380,496.0−293,571.0−242,482.0▲39.7%—
Other income, net
−2,812.011,813.031,983.06,866.0−1,779.0636.0——
Pretax income
−155,463.0−288,284.0−465,892.0−373,630.0−295,350.0−241,846.0▲38.1%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−155,463.0−288,284.0−465,892.0−373,630.0−295,350.0−241,846.0▲38.1%—
Per share
Diluted EPSbuyback-sensitive
−8.14−12.85−21.90−19.99−17.23−14.63▲41.3%—
Diluted shares (mn)
30.3122.4321.2718.6917.1416.54▲5.5%+7.9%
Margins
Gross margin
—A—A—A—————
Operating margin
−10.7%−31.3%−276.4%———▲245.1pp—
Net margin26th pct in Healthcare
−10.9%−30.1%−258.6%———▲228.6pp—
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Madrigal Pharmaceuticals' revenue last fiscal year?

Madrigal Pharmaceuticals reported revenue of $958.4M in fiscal 2025, up 432.1% from fiscal 2024.

What was Madrigal Pharmaceuticals' net income?

Madrigal Pharmaceuticals reported net income of −$288.3M in fiscal 2025, a net margin of −30.1%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.